Clearside Bio

Clearside Biomedical is an intellectual property holding and commercialization company that owns a portfolio of patents covering a suprachoroidal space ocular drug-delivery platform and microinjector technology. The company emerged from Chapter 11 bankruptcy in 2026 and is focused on monetizing and utilizing its retained intellectual property assets.